Abstract:BackgroundCoumarin (2H-chromen-2-one) and its derivatives have a wide range of biological and pharmaceutical activities. They possess antitumor, anti-HIV, anticoagulant, antimicrobial, antioxidant, and anti-inflammatory activities. Synthesis and isolation of coumarins from different species have attracted the attention of medicinal chemists. Herein, we report the synthesis, molecular structure, dielectric, anticancer activity and docking studies with the potential target protein tankyrase.ResultsMolecular structure of (3E)-3-(4-methylbenzylidene)-3,4-dihydro-2H-chromen-2-one (MBDC) is derived from quantum chemical calculations and compared with the experimental results. Intramolecular interactions, stabilization energies, and charge delocalization are calculated by NBO analysis. NLO property and dielectric quantities have also been determined. It indicates the formation of a hydrogen bonding between –OH group of alcohol and C=O of coumarin. The relaxation time increases with the increase of bond length confirming the degree of cooperation and depends upon the shape and size of the molecules. The molecule under study has shown good anticancer activity against MCF-7 and HT-29 cell lines. Molecular docking studies indicate that the MBDC binds with protein.ConclusionsIn this study, the compound (3E)-3-(4-methylbenzylidene)-3,4-dihydro-2H-chromen-2-one was synthesized and characterized by spectroscopic studies. The computed and experimental results of NMR study are tabulated. The dielectric relaxation studies show the existence of molecular interactions between MBDC and alcohol. Theoretical results of MBDC molecules provide the way to predict various binding sites through molecular modeling and these results also support that the chromen substitution is more active in the entire molecule. Molecular docking study shows that MBDC binds well in the active site of tankyrase and interact with the amino acid residues. These results are compared with the anti cancer drug molecule warfarin derivative. The results suggest that both molecules have comparable interactions and better docking scores. The results of the antiproliferative activity of MBDC and Warfarin derivative against MCF-7 breast cancer and HT-29 colon cancer cell lines at different concentrations exhibited significant cytotoxicity. The estimated half maximal inhibitory concentration (IC 50) value for MBDC and Warfarin derivative was 15.6 and 31.2 μg/ml, respectively. This enhanced cytotoxicity of MBDC in MCF-7 breast cancer and HT-29 colon cancer cell lines may be due to their efficient targeted binding and eventual uptake by the cells. Hence the compound MBDC may be considered as a drug molecule for cancer.Graphical abstractThe binding mode of the ligand MBDC at active site of protein and the graphical representation of cell inhibition for MCF-7 and HT-29 cell lines.

Heteroaromatization of Coumarin Part III: One-Pot Synthesis, Antitumor Activity, DFT Studies, and Molecular Docking of Coumarin Derivatives

Heteroaromatization of Coumarin Part I: Design, Synthesis, Reactions, Antitumor Activities of Novel Pyridine and Naphthyridine Derivatives

Heteroaromatization of Coumarin Part II: Synthesis, Reactions, Antimicrobial Activities of Novel Pyrido[2,3-d]pyrimidine Derivatives

Design, Synthesis and Biological Evaluation of Novel 3-Substituted 4-Anilino-coumarin Derivatives As Antitumor Agents

Three-Component Synthesis of Some New Coumarin Derivatives as Anticancer Agents

Synthesis and Anticancer Evaluation of Novel Coumarin Derivatives

Synthesis and Antitumor Activities of Novel 3-Arylcoumarins

Design of New Benzo[h]chromene Derivatives: Antitumor Activities and Structure-Activity Relationships of the 2,3-Positions and Fused Rings at the 2,3-Positions

Multicomponent reactions of cyanoacetanilide derivatives: Synthesis of coumarin and quinoline derivative and evaluations of their cytotoxicity

Synthesis and Biological Evaluation of a Novel Class of Coumarin Derivatives.

Synthesis, spectroscopic, dielectric, molecular docking and DFT studies of (3E)-3-(4-methylbenzylidene)-3,4-dihydro-2H-chromen-2-one: an anticancer agent

Novel 4-Hydroxycoumarin Derivatives: Anti-Cancer Effects on Human Oral Cancer Cells

Novel Coumarin‐Pyrazole‐Thiazoles Hybrids: Synthesis, Anticancer Activity, Molecular Docking and In Silico ADMET prediction Studies

Synthesis and Characterization of 7-Diethylamino-4-Chloromethyl Coumarin: Spectroscopic Analysis, Molecular Docking, and Anticancer Activity on Large Intestine Carcinoma Cells

SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY STUDY OF NOVEL COUMARIN DERIVATIVES

Synthesis and Cytotoxic Activity of Coumarin Derivatives Containing Benzotriazole Moieties

Effective Synthesis and Biological Evaluation of Dicoumarols: Preparation, Characterization, and Docking Studies

Synthesis and Bioactivities of Penta-1,4-dien-3-one Derivatives Containing a Coumarin Moiety

Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2

Synthesis and antiproliferative evaluation of novel 3,5,8-trisubstituted coumarins against breast cancer

Design, Synthesis, and in Vitro Evaluation of Novel 3, 7‐disubstituted Coumarin Derivatives As Potent Anticancer Agents